Holen Sie sich die Stockscreener-App
5.696
3.22%
-0.199
Schlusskurs vom Vortag:
$5.895
Offen:
$5.76
24-Stunden-Volumen:
879.22K
Relative Volume:
0.11
Marktkapitalisierung:
$444.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.96M
KGV:
-1.8025
EPS:
-3.16
Netto-Cashflow:
$-176.27M
1W Leistung:
+6.04%
1M Leistung:
-0.09%
6M Leistung:
-52.54%
1J Leistung:
-45.35%
1-Tages-Spanne:
$5.65
$5.87
1-Wochen-Bereich:
$5.33
$6.1499
52-Wochen-Spanne:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Vergleichen Sie REPL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
5.695 | 460.53M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.08 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.41 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.12 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
730.94 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.37 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Replimune's Regulatory Setback and Legal Exposure: A Cautionary Tale for Biotech Investors - AInvest
Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug ApprovalHagens Berman - PR Newswire
Replimune Group Inc. stock trend outlook and recovery pathLong Setup & Expert Approved Momentum Trade Ideas - Newser
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline September 22, 2025 - ACCESS Newswire
Will Replimune Group Inc. continue its uptrendLong Setup & Real-Time Chart Breakout Alerts - Newser
Ranking Replimune Group Inc. among high performing stocks via toolsGap Up & Growth Focused Stock Reports - Newser
Real time alert setup for Replimune Group Inc. performance2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
American Century Companies Inc. Grows Stake in Replimune Group, Inc. $REPL - Defense World
Developing predictive dashboards with Replimune Group Inc. dataJuly 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - WV News
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
Replimune’s Regulatory Crossroads: Can RP1 Navigate FDA Hurdles in Advanced Melanoma? - AInvest
Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Recover LossesContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Can you recover from losses in Replimune Group Inc.July 2025 Breakouts & Free Community Consensus Stock Picks - Newser
Risk vs reward if holding onto Replimune Group Inc.2025 Retail Activity & Precise Swing Trade Entry Alerts - Newser
Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha
What Fibonacci levels say about Replimune Group Inc. reboundMarket Risk Report & Real-Time Buy Signal Alerts - Newser
What’s the recovery path for long term holders of Replimune Group Inc.Trade Ideas & Daily Profit Maximizing Tips - Newser
Full technical analysis of Replimune Group Inc. stockQuarterly Earnings Summary & Verified Stock Trade Ideas - Newser
What MACD signals say about Replimune Group Inc.Index Update & Consistent Growth Equity Picks - Newser
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Class Action Reminder for REPL Investors: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors of Securities Fraud Class Action Lawsuit - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key DrugHagens Berman - GlobeNewswire
Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineREPL - WV News
Replimune Announces Type A Meeting Scheduled with FDA - The Manila Times
Critical FDA Meeting Scheduled: Replimune's Advanced Melanoma Treatment Faces Decisive Moment - Stock Titan
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline - ACCESS Newswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Detecting support and resistance levels for Replimune Group Inc.Market Activity Summary & AI Driven Stock Price Forecasts - Newser
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
Class Action Lawsuit Filed: Replimune Group, Inc. (REPL)Join by September 22, 2025 – Contact Levi & Korsinsky - ACCESS Newswire
Can Replimune Group Inc. continue delivering strong returnsQuarterly Market Summary & Proven Capital Preservation Tips - خودرو بانک
Replimune Faces Big Swings After FDA Setback And Cash Concerns - Finimize
News impact scoring models applied to Replimune Group Inc.Portfolio Update Report & Weekly Setup with High ROI Potential - Newser
Kessler Topaz Meltzer & Check, LLP Encourages Replimune Group, Inc. Investors With Losses to Contact the Firm - NewMediaWire
Identifying reversal signals in Replimune Group Inc.July 2025 Selloffs & Verified Momentum Stock Ideas - Newser
Replimune Group Inc. Builds Base for Possible Rebound getLinesFromResByArray error: size == 0 - thegnnews.com
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
How to build a dashboard for Replimune Group Inc. stockPrice Action & AI Driven Stock Movement Reports - Newser
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL | FinancialContent - FinancialContent
REPL Class Action Lawsuit Reminder: Kessler Topaz Meltzer & - GlobeNewswire
Replimune Group Inc. stock prediction for this weekMarket Growth Summary & Stock Portfolio Risk Control - Newser
REPL Class Action Reminder: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Replimune Group, Inc. Class Action Lawsuit - Morningstar
Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Astley-Sparke Philip | Director |
May 20 '25 |
Sale |
8.06 |
32,279 |
260,169 |
1,405,071 |
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
1.37%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):